https://microbioncorp.com/_news/microbion-corporation-announces-data-highlighting-in-vitro-activity-of-pravibismane-in-ntm-including-activity-against-ntm-causing-intracellular-infections-to-be-presented-at-the-colorado-mycobacteria-conference-2022 0.1 2022-06-06 https://microbioncorp.com/_news/microbion-corporation-announces-granting-of-a-us-patent-for-the-use-of-topical-pravibismane-for-diabetic-foot-ulcer-infections 0.1 2022-06-06 https://microbioncorp.com/_news/microbion-corporation-receives-up-to-2-1-million-in-funding-support-from-the-us-navy-in-partnership-with-cubrc-inc-to-advance-topical-pravibismane 0.1 2022-06-06 https://microbioncorp.com/_news/microbion-corporation-announces-granting-of-a-us-patent-for-a-pharmaceutical-composition-of-pravibismane 0.1 2022-10-03 https://microbioncorp.com/_news/microbion-corporation-announces-data-highlighting-pravibismane-s-effect-on-bacterial-energetics-presented-at-asm-microbe-2022 0.1 2022-10-07 https://microbioncorp.com/_news/microbion-corporation-announces-poster-highlighting-pravibismane-activity-against-common-cystic-fibrosis-pulmonary-pathogens-to-be-presented-at-the-north-american-cystic-fibrosis-conference-2022 0.1 2022-11-03 https://microbioncorp.com/_news/microbion-corporation-appoints-robert-a-gillam-as-chairman-of-microbion-s-board-of-directors 0.1 2021-07-28 https://microbioncorp.com/_news/microbion-corporation-initiates-phase-2-clinical-study-evaluating-topical-pravibismane-treatment-of-diabetic-foot-infections 0.1 2023-03-08 https://microbioncorp.com/_news/microbion-corporation-receives-additional-funding-support-from-the-cystic-fibrosis-foundation-to-speed-advancement-of-inhaled-pravibismane 0.1 2021-06-07 https://microbioncorp.com/_news/microbion-corporation-announces-generic-name-for-lead-antimicrobial-compound-pravibismane 0.1 2021-06-07 https://microbioncorp.com/_news/microbion-corporation-announces-litigation-settlement-agreement-including-a-license-agreement-with-nyu-langone-health 0.1 2021-06-07 https://microbioncorp.com/_news/microbion-corporation-announces-orphan-drug-designation-granted-for-pravibismane-suspension-for-inhalation-by-us-fda 0.1 2021-06-07 https://microbioncorp.com/_news/microbion-announces-positive-topline-results-from-phase-2-study-of-topical-pravibismane-for-moderately-infected-diabetic-foot-ulcers 0.1 2024-11-12 https://microbioncorp.com/_news/microbion-corp-granted-us-patent-for-the-use-of-inhaled-pravibismane-for-pulmonary-infections 0.1 2023-04-03 https://microbioncorp.com/_news/microbion-corp-presents-a-poster-on-pravibismane-s-activity-against-diabetic-foot-infection-patient-isolates 0.1 2023-05-09 https://microbioncorp.com/_news/microbion-to-present-new-data-demonstrating-that-pravibismane-disrupts-bacterial-bioenergetics-at-asm-microbe-2023 0.1 2023-06-16 https://microbioncorp.com/team/brett-baker 0.8 2021-10-20 https://microbioncorp.com/_news/microbion-to-present-design-of-ongoing-phase-2-study-treating-diabetic-foot-ulcer-infections-at-the-2023-military-health-system-research-symposium 0.1 2023-08-14 https://microbioncorp.com/_news/microbion-ceo-to-participate-in-panel-discussion-at-biofuture-2023 0.1 2023-10-06 https://microbioncorp.com/_news/microbion-s-pravibismane-granted-second-fda-orphan-drug-designation-for-the-treatment-of-non-tuberculous-mycobacterial-ntm-infections 0.1 2024-01-29 https://microbioncorp.com/_news/microbion-s-topical-pravibismane-phase-1b-moderate-or-severe-diabetic-foot-ulcer-infection-study-is-published-in-international-wound-journal 0.1 2024-04-03 https://microbioncorp.com/_news/microbion-corporation-ceo-to-present-at-the-2023-bio-ceo-investor-conference 0.1 2023-02-03 https://microbioncorp.com/team/michelle-yang 0.0 2019-02-26 https://microbioncorp.com/team/jason-j-harmon 0.0 2019-02-26 https://microbioncorp.com/press/bozeman-s-microbion-is-fighting-to-save-lives-inside-the-war-on-antimicrobial-resistance 0.5 2021-06-07 https://microbioncorp.com/_news/microbion-presented-new-pravibismane-data-against-mycobacteroides-abscessus-at-the-6th-world-bronchiectasis-and-ntm-conference 0.1 2023-08-14 https://microbioncorp.com/_news/microbion-selected-to-present-at-advanced-wound-care-summit-usa 0.1 2024-04-12 https://microbioncorp.com/_news/microbion-receives-award-at-advanced-wound-care-summit-usa-s-innovation-showcase 0.1 2024-04-24 https://microbioncorp.com/about/investors.htm 0.9 2021-06-07 https://microbioncorp.com/science/technology.htm 0.9 2025-12-12 https://microbioncorp.com/pipeline/diabetic-foot-ulcer.htm 0.9 2025-12-12 https://microbioncorp.com/pipeline/respiratory 0.8 2025-12-12 https://microbioncorp.com/about/team.htm 0.9 2021-06-07 https://microbioncorp.com/news 0.8 2021-06-07 https://microbioncorp.com/contact.htm 0.9 2021-06-07 https://microbioncorp.com/ 1.0 2021-06-07 https://microbioncorp.com/ 1.0 2021-06-07 https://microbioncorp.com/subscribe 0.5 2021-06-07 https://microbioncorp.com/about/partnerships.htm 0.9 2025-12-12 https://microbioncorp.com/science/biofilms.htm 0.9 2025-12-12 https://microbioncorp.com/about/careers 0.5 2025-12-12 https://microbioncorp.com/_news/5n-plus-acquires-stake-in-microbion-and-secures-drug-substance-manufacturing-rights 0.1 2021-06-07 https://microbioncorp.com/_news/mbn-101-received-fda-qidp-designation-for-adjunctive-treatment-of-moderate-severe-dfi 0.0 2021-06-07 https://microbioncorp.com/_news/quark-venture-gf-securities-invest-us-25m-in-microbion-to-advance-new-class-of-drugs 0.0 2021-06-07 https://microbioncorp.com/_news/mbn-101-received-fda-fast-track-designation-adjunctive-treatment-of-diabetic-foot-ulcer-infections 0.0 2021-06-07 https://microbioncorp.com/press/bozeman-pharmaceutical-company-awarded-17m-in-grants-for-drug-development 0.5 2021-06-07 https://microbioncorp.com/_news/microbion-awarded-up-to-17-1-million-from-carb-x-and-the-cystic-fibrosis-foundation-to-develop-inhaled-antimicrobial-for-chronic-respiratory-infections-in-cf 0.1 2021-06-07 https://microbioncorp.com/_news/microbion-corporation-announces-first-patient-treated-in-phase-2a-orthopedic-infection-trial 0.0 2021-06-07 https://microbioncorp.com/pipeline/orthopedic-implant 0.8 2025-12-12 https://microbioncorp.com/_news/microbion-corporation-announces-results-from-randomized-double-blind-placebo-controlled-phase-1b-trial-of-pravibismane-mbn-101-for-treatment-of-moderate-to-severe-chronic-infected-diabetic-foot-ulcers 0.1 2021-06-07 https://microbioncorp.com/pipeline/publications 0.5 2025-12-12 https://microbioncorp.com/_news/microbion-corporation-to-present-data-highlighting-broad-spectrum-activity-of-bisedt-at-the-29th-european-congress-of-clinical-microbiology-infectious-diseases-eccmid- 0.0 2021-06-07